Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

France's Sanofi pins hopes on new drugs after setbacks

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/13/2017 | 04:24pm CET
FILE PHOTO: A logo is seen in front of the entrance at the headquarters of French drugmaker Sanofi in Paris

Sanofi's (>> Sanofi) promising pipeline of experimental drugs can help it overcome setbacks including the low uptake of a new cholesterol treatment and concerns about a dengue vaccine, the French pharmaceuticals group said on Wednesday.

Sanofi's (>> Sanofi) promising pipeline of experimental drugs can help it overcome setbacks including the low uptake of a new cholesterol treatment and concerns about a dengue vaccine, the French pharmaceuticals group said on Wednesday.

The world's sixth largest drugmaker, battling to contain the fallout from a safety row in the Philippines over dengue vaccine Dengvaxia, said it expected to file nine medicines for regulatory assessment in the next 18 months.

Shares in Sanofi were down 0.77 percent at 1510 GMT.

Some investors have voiced discontent with the group's product pipeline and its failure to make a large acquisition since it appointed Olivier Brandicourt as chief executive in 2015.

Sanofi is under pressure to stand out in research and development as its diabetes division still has to overcome pricing constraints in the United States, the world's largest health market, where its blockbuster insulin medication Lantus has lost its patent.

In opening remarks at a company investor day, Brandicourt said the group was "on track" to sell its European generic drugs unit in "the coming year", a long-awaited deal which could be worth more than 2 billion euros ($2.35 billion), sources say.

"We are making good progress overall on our roadmap and I am confident that Sanofi now is much better positioned to deliver the sustained and long term growth that our shareholders are expecting from us," he said.

The company said in November 2015 its five-year strategic plan would see six key launches likely to generate peak sales of 12 billion to 14 billion euros by 2025.

One of them, Dengvaxia, is proving disappointing after findings the vaccine could, in some cases, increase the risk of severe dengue in recipients not previously infected by the virus.

Once touted as a $1 billion-a-year blockbuster product, Dengvaxia's initial sales last year were only 55 million euros.

Hurdles to patient access by health insurers and pharmacy benefit managers have also led to disappointing sales in Sanofi's new cholesterol drug Praluent.

"When I turn to delivering outstanding launches, I concede that our record over the past two years has been mixed," Brandicourt said. "While we are not changing our ambition of combined peak sales, we are clearly much more reliant on our immunology franchise."

'MULTI-TARGETING'

In immunology, Sanofi has been concentrating on "multi-targeting" drugs that have the potential to treat more than one disease.

One example is dupilumab, which was developed with U.S partner Regeneron (>> Regeneron Pharmaceuticals) and for which it has secured approval in the United States and Europe to treat eczema. The drug is also expected to have further uses in asthma, nasal polyps, eosinophilic esophagitis and food allergies.

"Phase 3 development for dupilumab is now planned in chronic obstructive pulmonary disease (COPD)," Sanofi said.

Sanofi, whose shares have underperformed major rivals, reiterated its strategy to rebuild its position in cancer and said it expected a first regulatory submission of its monoclonal antibody for relapsed refractory multiple myeloma in 2018.

The drug will compete with Genmab's (>> Genmab) and Johnson & Johnson's (J&J) (>> Johnson & Johnson) Darzalex which is already on the market.

DIVERSIFIED

The Cancer Research Institute said last week the race to come up with new immunotherapy treatments for cancer had sparked an unprecedented expansion in the oncology drug pipeline, with more than 2,000 immune-system-boosting agents in development.

The result is a scramble for patients to enrol in clinical trials, duplication of effort and the likely ultimate failure of many projects, according to experts.

Asked if Sanofi had the means to pursue its strategy in multiple indications while some other players have opted to focus on niche products or key drugs, Brandicourt said Sanofi had made a clear choice to remain diversified.

"There is no miracle recipe," he said. "But given the risks in the industry, we came to the conclusion that being active in one therapeutic area only was dangerous."

($1 = 0.8505 euros)

(Editing by Edmond Blair and Mark Potter)

By Matthias Blamont

Stocks treated in this article : Sanofi, Johnson & Johnson, Regeneron Pharmaceuticals, Genmab
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
12/13 France's Sanofi pins hopes on new drugs after setbacks
12/13 THE POWER OF GLOBAL TALENT : Johnson & Johnson Joins the Coalition for the Ameri..
12/13 MICROBOT MEDICAL : P. (Laxmin) Laxminarain Appointed to Microbot Medicals Board ..
12/13 JOHNSON & JOHNSON : Youth schooled on HIV/AIDS prevention and non-discrimination
12/12 JOHNSON & JOHNSON : LSP closes second health economic fund at EUR 280M
12/12 JOHNSON & JOHNSON : DARZALEX® (daratumumab) Combination Regimen Significantly Im..
12/12 JOHNSON & JOHNSON : Motus GI Appoints Gary J. Pruden, Former Worldwide Chairman ..
12/12 JOHNSON & JOHNSON : Joins HIV Campaign
12/12 Sanofi investors hungry for drug progress and deal news
12/12 JOHNSON & JOHNSON : New Data for DARZALEX® (daratumumab) Presented at ASH 2017 S..
More news
News from SeekingAlpha
12/13 RETIREMENT STRATEGY : Applying My Simple Strategy To The Dividend King Retiremen..
12/13 I'm Sticking With CVS And Walgreens, My Last Two Losers
12/12 MCDONALD'S : Dividend Increase For Income And Good Total Return
12/12 Positive Market In 2017 - Cramer's Mad Money (12/11/17)
12/11 Johnson & Johnson files U.S. marketing application for expanded label use of ..
Financials ($)
Sales 2017 76 324 M
EBIT 2017 23 523 M
Net income 2017 16 391 M
Debt 2017 17 115 M
Yield 2017 2,35%
P/E ratio 2017 23,91
P/E ratio 2018 19,67
EV / Sales 2017 5,24x
EV / Sales 2018 4,84x
Capitalization 383 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 146 $
Spread / Average Target 2,1%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.01%218 773
PFIZER10.04%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659
AMGEN19.97%128 363